Oncternal Therapeutics Faces Challenges with 37% Layoff and Clinical Trial Cessation

Friday, 13 September 2024, 07:42

Oncternal Therapeutics faces significant changes, as it announces a 37% workforce reduction amid exploring strategic alternatives. The layoffs, including the CMO, affect around 10 employees, as the company discontinues two clinical trials for its oncology drugs. Facing financial challenges, Oncternal is evaluating asset sales and potential mergers for its future viability.
LivaRava_Medicine_Default.png
Oncternal Therapeutics Faces Challenges with 37% Layoff and Clinical Trial Cessation

Oncternal Therapeutics Workforce Reduction

Oncternal Therapeutics is implementing a substantial workforce reduction of approximately 10 employees, totaling about 37% of its workforce. Effective October 1, Chief Medical Officer Salim Yazji will depart as the company explores strategic alternatives, including potential asset sales or a merger.

Discontinuation of Clinical Trials

Additionally, Oncternal is ceasing clinical trials for two oncology drugs: ONCT-534 and ONCT-808. While ONCT-534 failed to show clinically meaningful improvements, interim results from ONCT-808 indicated some anti-tumor activity.

  1. Interim Phase I for ONCT-534: No clinically meaningful disease improvements.
  2. ONCT-808 Results: A complete metabolic response lasting eight months was observed, but one severe complication resulted in a fatality.

Financial Situation and Future Plans

In an SEC filing, Oncternal reported cash reserves of $21.4 million with a substantial accumulated deficit of $214.7 million. The company anticipates ongoing net losses and the need for substantial additional financing in the coming years.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe